Role of sulodexide in the treatment of CVD

Area of Science:

• Vascular Medicine and Pathophysiology
• Pharmacology of Vascular Diseases

Background:

• Chronic venous disease (CVD) treatment requires understanding its complex pathophysiology.
• Emerging theories emphasize inflammation, endothelial glycocalyx dysfunction, and extracellular matrix changes in CVD development.

Purpose of the Study:

• To summarize current pathophysiological knowledge of CVD.
• To review the role of sulodexide in managing CVD.
• To connect recent research with sulodexide's therapeutic potential.

Main Methods:

• Literature review of recent research on CVD pathophysiology.
• Analysis of hemodynamic factors in large veins and microcirculation.
• Evaluation of endothelial function and inflammatory markers.
• Assessment of sulodexide's application in CVD treatment.

Main Results:

• CVD pathophysiology involves hemodynamics, endothelial dysfunction, and inflammation.
• Endothelial glycocalyx damage and matrix alterations are critical in CVD.
• Sulodexide is identified as a potential therapeutic agent for CVD.
• Sulodexide may alleviate symptoms across all CEAP classes (C1-C6).

Conclusions:

• A deeper understanding of CVD pathophysiology supports sulodexide's use.
• Sulodexide offers a potential treatment for edema and trophic changes in CVD.
• Active management with sulodexide can improve outcomes in chronic venous disease.